Conmed (NYSE:CNMD) Bolsa

Conmed

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Conmed Corp

<p>Throughout the last three months, 4 analysts have evaluated Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $76.5, a high estimate of $91.00, and a low estimate of $70.00. Highlighting a 6.71% decrease, the current average has fallen from the previous average price target of $82.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738875615_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Conmed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Conmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Conmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Conmed's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Conmed analyst ratings.</strong></a></p>
<h2>All You Need to Know About Conmed</h2>
<p>Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.</p>
<h3>Understanding the Numbers: Conmed's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Conmed's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>3.98%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Conmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>15.47%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.4%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Conmed's ROA excels beyond industry benchmarks, reaching <strong>2.13%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.01</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

CNMD

Breaking Down Conmed: 4 Analysts Share Their Views

<p>Stifel  analyst Rick Wise   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and raises the price target from $72 to $75.</p>


News

Price Target

Stifel Maintains Buy on Conmed, Raises Price Target to $75

<p>Wells Fargo  analyst Vik Chopra   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $74 to $70.</p>


Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $70

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Evercore ISI Group analyst Shweta Khajuria downgraded the rating for <strong>Match Group, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Outperform to In-Line and maintained the price target of $35. Match Group shares closed at $33.58 on Wednesday. <a href="https://www.benzinga.com/quote/MTCH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Vijay Rakesh downgraded <strong>Skyworks Solutions, In</strong>c. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) from Outperform to Neutral and lowered the price target from $105 to $62. Skyworks Solutions shares closed at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Robbie Marcus downgraded <strong>CONMED Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Overweight to Neutral and cut the price target from $85 to $70. Conmed shares closed at $74.00 on Wednesday. <a href="https://www.benzinga.com/quote/CNMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Craig Ellis downgraded the rating for <strong>FormFactor, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) from Buy to Neutral and lowered the price target from $64 to $34. FormFactor shares closed at $41.12 on Wednesday. <a href="https://www.benzinga.com/quote/FORM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Alex Scott downgraded <strong>Voya Financial, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) from Overweight to Equal-Weight and maintained the price target of $75. Voya Financial shares closed at $72.22 on Wednesday. <a href="https://www.benzinga.com/quote/VOYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying MTCH stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-1024x576.png" alt="" class="wp-image-769131" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Downgrades

Pre-Market Outlook

Markets

Trading Ideas

FORM

MTCH

SWKS

VOYA

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

<p><strong>CONMED Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) posted better-than-expected earnings for its fourth quarter, but issued FY25 <a href="https://www.benzinga.com/quote/CNMD/earnings">earnings and revenue guidance below estimates.</a></p>
<p>Conmed reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 per share. The company reported quarterly sales of $345.94 million which beat the analyst consensus estimate of $341.01 million.</p>
<p>&#8220;2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability,&#8221; commented Patrick J. Beyer, CONMED&#8217;s President and Chief Executive Officer. &#8220;In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.&#8221;</p>
<p>Conmed said it sees FY2025 adjusted EPS of $4.25-4.40, versus market estimates of $4.74. The company expects sales of $1.344 billion-1.372 billion, versus projections of $1.40 billion.</p>
<p>Conmed shares gained 1.5% to close at $74.00 on Wednesday.</p>
<p>These analysts made changes to their price targets on Conmed following earnings announcement.</p>
<ul>
<li>JP Morgan analyst Robbie Marcus downgraded Conmed from Overweight to Neutral and lowered the price target from $85 to $70.</li>
<li>Needham analyst Mike Matson maintained Conmed with a Buy and lowered the price target from $97 to $91..</li>
</ul>
<p><strong>Considering buying CNMD stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-1024x595.png" alt="" class="wp-image-769181" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Earnings

These Analysts Slash Their Forecasts On Conmed After Q4 Results

WIIM

Conmed shares are trading lower after the company issued FY25 earnings and revenue guidance below estimates. JPMorgan downgraded the stock from Overweight to Neutral.

<p>Needham  analyst Mike Matson   maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and lowers the price target from $97 to $91.</p>


Needham Maintains Buy on Conmed, Lowers Price Target to $91

<p>JP Morgan  analyst Robbie Marcus   downgrades Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Overweight to Neutral and lowers the price target from $85 to $70.</p>


JP Morgan Downgrades Conmed to Neutral, Lowers Price Target to $70

Conmed shares are trading lower after the company issued FY25 earnings and revenue guidance below estimates.

CONMED shares are trading lower after the company issued FY25 guidance below estimates.

<p><strong>Conmed</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) announced its Q4 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Conmed beat estimated earnings by 12.0%, reporting an EPS of $1.34 versus an estimate of $1.2.</p>
<p>Revenue was up $18.90 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.06, leading to a 5.0% increase share price change the next day.</p>
<p>Here's a look at Conmed's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.91</td>
<td>0.74</td>
<td>1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.05</td>
<td>0.98</td>
<td>0.79</td>
<td>1.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>318.13M</td>
<td>332.32M</td>
<td>306.78M</td>
<td>332.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>316.70M</td>
<td>332.10M</td>
<td>312.27M</td>
<td>327.05M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Conmed management provided guidance for FY 2025, expecting earnings between $4.25 and $4.4 per share.</p>
<p>To track all earnings releases for Conmed <a href="https://www.benzinga.com/quote/CNMD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Conmed Q4 Earnings Assessment

<p><strong>Conmed</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) just disclosed its Q4 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Conmed beat estimated earnings by 12.0%, reporting an EPS of $1.34 versus an estimate of $1.2.</p>
<p>Revenue was up $18.90 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.06 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at Conmed's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.91</td>
<td>0.74</td>
<td>1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.05</td>
<td>0.98</td>
<td>0.79</td>
<td>1.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>318.13M</td>
<td>332.32M</td>
<td>306.78M</td>
<td>332.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>316.70M</td>
<td>332.10M</td>
<td>312.27M</td>
<td>327.05M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Conmed management provided guidance for FY 2025, expecting earnings between $4.25 and $4.4 per share.</p>
<p>To track all earnings releases for Conmed <a href="https://www.benzinga.com/quote/CNMD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Conmed Q4 Earnings Summary & Key Takeaways

<p><strong>Conmed</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Conmed beat estimated earnings by 12.0%, reporting an EPS of $1.34 versus an estimate of $1.2.</p>
<p>Revenue was up $18.90 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.06, leading to a 5.0% increase share price change the next day.</p>
<p>Here's a look at Conmed's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.91</td>
<td>0.74</td>
<td>1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.05</td>
<td>0.98</td>
<td>0.79</td>
<td>1.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>318.13M</td>
<td>332.32M</td>
<td>306.78M</td>
<td>332.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>316.70M</td>
<td>332.10M</td>
<td>312.27M</td>
<td>327.05M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Conmed management provided guidance for FY 2025, expecting earnings between $4.25 and $4.4 per share.</p>
<p>To track all earnings releases for Conmed <a href="https://www.benzinga.com/quote/CNMD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Conmed Q4 Earnings

<p>The earnings results for <strong>Conmed</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) for Q4 were made public on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Conmed beat estimated earnings by 12.0%, reporting an EPS of $1.34 versus an estimate of $1.2.</p>
<p>Revenue was up $18.90 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.06 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at Conmed's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.91</td>
<td>0.74</td>
<td>1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.05</td>
<td>0.98</td>
<td>0.79</td>
<td>1.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>318.13M</td>
<td>332.32M</td>
<td>306.78M</td>
<td>332.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>316.70M</td>
<td>332.10M</td>
<td>312.27M</td>
<td>327.05M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Conmed management provided guidance for FY 2025, expecting earnings between $4.25 and $4.4 per share.</p>
<p>To track all earnings releases for Conmed <a href="https://www.benzinga.com/quote/CNMD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Conmed: Q4 Earnings Insights

<p>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) is looking for FY2025 Adj EPS of $4.25-4.40 vs $4.74 analyst estimate. sees sales of $1.344 billion-1.372 billion vs $1.40 billion estimate.</p>


Guidance

Conmed Sees FY2025 Adj EPS $4.25-4.40 vs $4.74 Est; Sees Sales $1.344B-1.372B vs $1.40B Est

<p>The earnings results for <strong>Conmed</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) for Q4 were made public on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Conmed beat estimated earnings by 12.0%, reporting an EPS of $1.34 versus an estimate of $1.2.</p>
<p>Revenue was up $18.90 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.06, leading to a 5.0% increase share price change the next day.</p>
<p>Here's a look at Conmed's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.91</td>
<td>0.74</td>
<td>1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.05</td>
<td>0.98</td>
<td>0.79</td>
<td>1.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>318.13M</td>
<td>332.32M</td>
<td>306.78M</td>
<td>332.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>316.70M</td>
<td>332.10M</td>
<td>312.27M</td>
<td>327.05M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Conmed <a href="https://www.benzinga.com/quote/CNMD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Conmed Q4

<p>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 by 11.67 percent. This is a 26.42 percent increase over earnings of $1.06 per share from the same period last year.  The company reported quarterly sales of $345.94 million which beat the analyst consensus estimate of $341.01 million by 1.45 percent.  This is a 5.78 percent increase over sales of $327.05 million the same period last year.</p>


Earnings Beats

Conmed Q4 Adj $1.34 Beats $1.20 Estimate, Sales $345.94M Beat $341.01M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

<p>As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Conmed Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>)</strong></h3>
<ul>
<li>On Oct. 30, Conmed reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of 99 cents per share. &#8220;Our third quarter results were largely in line with our expectations, and we remain focused on getting fully back on offense,&#8221; commented Curt R. Hartman, CONMED&#8217;s Chair of the Board, President, and Chief Executive Officer. &#8220;I am particularly proud of how our teams responded to the disruption from hurricanes Helene and Milton, which temporarily impacted our employees and facilities in the Southeast as well as many of our customers.&#8221; The company's stock gained around 21% over the past month and has a <a href="https://www.benzinga.com/quote/CNMD">52-week high of $117.27</a>.</li>
<li><strong>RSI Value:</strong> 70.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>CNMD Price Action:</strong> Shares of Conmed gained 4.5% to close at $74.91 on Friday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Madrigal Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>)</strong></h3>
<ul>
<li>On Oct. 31, Madrigal Pharmaceuticals reported better-than-expected third-quarter financial results. Bill Sibold, Chief Executive Officer of Madrigal, stated, &#8220;Our U.S. launch of Rezdiffra is progressing exceptionally well driven by the outstanding execution of our team. Growing adoption by prescribers, broader payer coverage and an increasing number of patients on therapy each contributed to the strong performance. This early success highlights the critical need for effective treatments for moderate to advanced NASH/MASH, which is expected to become the leading cause of liver transplants in the U.S.&#8221; The company's stock gained around 65% over the past month and<a href="https://www.benzinga.com/quote/MDGL"> has a 52-week high</a> of $368.29.</li>
<li><strong>RSI Value:</strong> 74.01</li>
<li><strong>MDGL Price Action:</strong> Shares of Madrigal Pharmaceuticals gained 5.5% to close at $347.45 on Friday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Butterfly Network Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>)</h3>
<ul>
<li>On Nov. 1, Butterfly Network reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates. The company's stock gained around 78% over the past month and has a <a href="https://www.benzinga.com/quote/BFLY">52-week high</a> of $3.55.</li>
<li><strong>RSI Value:</strong> 72.56</li>
<li><strong>BFLY Price Action:</strong> Shares of Butterfly Network fell 1.4% to close at $3.24 on Friday.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></strong></li>
</ul>


Short Ideas

BFLY

MDGL

Top 3 Health Care Stocks That May Dip This Month

<p>Needham  analyst Mike Matson   reiterates Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and maintains $97 price target.</p>


Reiteration

Needham Reiterates Buy on Conmed, Maintains $97 Price Target

Press Releases

CONMED Corporation Announces Leadership Succession

CONMED Corporation Announces Third Quarter 2024 Financial Results

CONMED Corporation to Participate in Fireside Chats at Two Investor Conferences on November 19-20

CONMED Corporation to Participate in a Fireside Chat at the Piper Sandler Healthcare Conference

CONMED Corporation Announces Quarterly Cash Dividend

CONMED Corporation to Present at the J.P. Morgan Healthcare Conference

CONMED Corporation to Announce Fourth Quarter 2024 Financial Results on February 5, 2025

CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

Comments

Conmed

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL